ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 28575464

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.

Sepúlveda-Sánchez JM and 15 others. Neuro Oncol, 2017. Cited by 103 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Papers, record 28575464. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28575464

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
PubMed
Journal
Neuro Oncol
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Multicenter Study
PubMed
Citations, by iCite
103
iCite
Relative citation ratio, by iCite
3.48
iCite
Revised in PubMed
2022-03-18
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sepúlveda-Sánchez JMJuan Manuel
2Vaz MÁMaría Ángeles
3Balañá CCarmen
4Gil-Gil MMiguel
5Reynés GGaspar
6Gallego ÓÓscar
7Martínez-García MMaría
8Vicente EElena
9Quindós MMaría
10Luque RRaquel

1 to 10 of 16Source PubMed

See all 16 authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Brain NeoplasmsMajor topic
ErbB ReceptorsMajor topic
Gene AmplificationMajor topic
GlioblastomaMajor topic
QuinazolinonesMajor topic
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Mutation
Prognosis
Signal Transduction
Survival Rate

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118,223,223Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.Clin Cancer Res2008https://conductscience.org/library/papers/18223223PubMed
223,429,996EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis.Acta Neuropathol2013https://conductscience.org/library/papers/23429996PubMed
312,067,969Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.Cancer Res2002https://conductscience.org/library/papers/12067969PubMed
425,691,693Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.Neuro Oncol2015https://conductscience.org/library/papers/25691693PubMed
519,018,475A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).J Neurooncol2009https://conductscience.org/library/papers/19018475PubMed
616,424,019Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.Cancer Res2006https://conductscience.org/library/papers/16424019PubMed
716,911,776Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.Diagn Pathol2006https://conductscience.org/library/papers/16911776PubMed
822,323,597Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22323597PubMed
922,753,918Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.J Clin Oncol2012https://conductscience.org/library/papers/22753918PubMed
1019,204,207Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.J Clin Oncol2009https://conductscience.org/library/papers/19204207PubMed

1 to 10 of 34

See all 34 references

Cited by93

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 103 citations.

PMIDTitleJournalYearIn PapersSource
42,958,602Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation.Exp Hematol Oncol2026https://conductscience.org/library/papers/42958602PubMed
42,824,982Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review.Front Med (Lausanne)2026https://conductscience.org/library/papers/42824982PubMed
42,649,915Construction Strategies, Microenvironmental Modelling and Precision-Therapy Applications of Glioma Organoid Models.Cancers (Basel)2026https://conductscience.org/library/papers/42649915PubMed
42,362,096Nerve growth factor receptor (NGFR): A key player in glioblastoma progression.Biochim Biophys Acta Rev Cancer2026https://conductscience.org/library/papers/42362096PubMed
42,298,055Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers.Int J Clin Oncol2026https://conductscience.org/library/papers/42298055PubMed
42,283,227Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.CNS Oncol2026https://conductscience.org/library/papers/42283227PubMed
41,886,013Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study.J Neurooncol2026https://conductscience.org/library/papers/41886013PubMed
41,827,793Translating Molecular Insights into Effective Targeting of Glioblastoma Stem Cells.Cancers (Basel)2026https://conductscience.org/library/papers/41827793PubMed
41,366,148Immunotherapy and targeted therapy for high grade gliomas: current and future directions.J Neurooncol2025https://conductscience.org/library/papers/41366148PubMed
41,304,872Cyclodextrin-Based Formulations as a Promising Strategy to Overcome the Blood-Brain Barrier: Historical Overview and Prospects in Glioblastoma Treatment.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41304872PubMed

1 to 10 of 93

See all 93 cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
TXK7,294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28575464

GET https://conductscience.org/api/papers/v1/28575464/references?page=2

API referenceFor AI assistants